When is Eikon Therapeutics the better choice?

The differentiating asset is an instrument, applying super resolution live cell microscopy to watch individual proteins move rather than measuring a static endpoint. Regulatory activity is real at the asset level with disclosed clinical work, and public reporting documents the capital position. The platform feeds medicinal chemistry decisions rather than claiming to replace them, which is an honest account of what it does.

When is Recursion the better choice?

High throughput cellular experimentation feeding machine learning on imaging and multiomic data at industrial scale, so the platform generates its own training data. Partnership economics are disclosed as a listed registrant, so the market's valuation of the platform is visible rather than described. Model hypotheses are tested in the wet laboratory before they advance, which puts empirical checking inside the loop.

Eikon Therapeutics vs Recursion

Last VerifiedAugust 4, 2026

Verdict

Two companies that built instruments rather than borrowing datasets, and they measure different things. Eikon watches proteins move inside living cells with super resolution microscopy descended from Nobel recognised imaging work, which produces dynamic measurement nobody else in this category has, and it has disclosed clinical work at the asset level. Recursion runs high throughput cellular experimentation at industrial scale, learning from images and multiomic data it generates itself, with disclosed partnership economics as a listed company and wet laboratory testing inside the loop. Both are strong platform arguments. Both also describe the optics and the assay beautifully while saying almost nothing about the models, which is the question a partner should press before signing anything.

Select Eikon Therapeutics if

The differentiating asset is an instrument, applying super resolution live cell microscopy to watch individual proteins move rather than measuring a static endpoint.
Regulatory activity is real at the asset level with disclosed clinical work, and public reporting documents the capital position.
The platform feeds medicinal chemistry decisions rather than claiming to replace them, which is an honest account of what it does.

Select Recursion if

High throughput cellular experimentation feeding machine learning on imaging and multiomic data at industrial scale, so the platform generates its own training data.
Partnership economics are disclosed as a listed registrant, so the market's valuation of the platform is visible rather than described.
Model hypotheses are tested in the wet laboratory before they advance, which puts empirical checking inside the loop.

Attribute Matrix

Side by Side

Axis	E Eikon Therapeutics	R Recursion
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.

Eikon Therapeutics vs insitro→Eikon Therapeutics vs Verge Genomics→Insilico Medicine vs Recursion→Recursion vs Schrödinger→Recursion vs Xaira Therapeutics→

Disclosure

Both describe their measurement approach clearly and their computational layer barely at all, which is the shared gap in instrument led discovery and the question to put to either: what do the models actually do with the imaging data. Neither publishes cell line or donor provenance, which is where the bias question lives for platforms learning from their own biology. Recursion narrowed its internal pipeline in 2025, so any breadth claim predating that should be checked against the current programme list. Neither holds a located security attestation.